Profile

Rapid Novor Inc. is a leading CRO specializing in antibody protein sequencing, discovery, and characterization. Founded in 2015 as a University of Waterloo spin-off, the company has developed the technology to directly sequence antibody proteins without needing access to genomic information. The company’s scientific capabilities have and continue to contribute directly to accelerating translational research. With over 10,000 successful projects completed globally, Rapid Novor is recognized for its rigor, innovation, and reliability. It operates Canada’s largest privately funded mass spectrometry-based proteomics facility, making it a top antibody protein sequencing, discovery, and characterization provider. Rapid Novor's mission is to advance human health by empowering researchers with deep antibody insights that drive diagnostics, therapeutic development, and translational research forward.

Product/Service Information:

As a trusted CRO partner, Rapid Novor supports pharmaceutical, biotechnology, and academic institutions. Core services include: (1) REmAb® - monoclonal antibody protein sequencing, (2) REpAb® - polyclonal antibody protein sequencing for antibody discovery, (3) Rapid HDX™ - Epitope/paratope mapping by HDX MS, (4) Rapid Characterization™ - Comprehensive antibody characterization analysis such as PTMs, Glycans, Intact Mass, Sequence variant, disulfide bonds, DAR, etc, (5) Rapid SPR™ - Antibody-antigen kinetics analysis.

Rapid Novor logo

Website

rapidnovor.com

Contact


Event details

Date: October 8 - 10, 2025

Event contact

Stephen Ip
Senior International Market Consultant
Japan and Korea

Participants

6 in total